Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 83 of the 90 references it cites were found in a registry or an index, and 3 are not checked yet; 73 of the 82 sources its claims cite were checked for support.

Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies

Open access
Henrykowska, Gabriela, Bartusik-Aebisher, Dorota, Dynarowicz, Klaudia, Ramesh, Tamil Selvan, Smolak, Barbara, Aebisher, David · 2026 · Pharmaceuticals

Abstract

Cetuximab and panitumumab are anti-EGFR monoclonal antibodies widely used for the treatment of colorectal cancers. However, due to various mechanisms of resistance to these targeted therapies, the patients’ responses vary. These resistances remain a major obstacle in treatment and overcoming them has become a key emphasis of current therapeutic strategies. Intrinsic and acquired resistance often lead to reactivation of downstream signaling pathways, mainly the RAS-RAF-MEK-ERK (MAPK pathway) and PI3K-AKT axes. Prior existing mutations in KRAS, NRAS, and BRAF result in primary resistance by constantly activating the signals, irrespective of EGFR inhibition. That said, acquired resistance manifests under therapeutic burden through the process of clonal evolution via KRAS and BRAF alterations, restoring MAPK pathway activity despite EGFR inhibition. In addition to those mutations, tumor cells exploit mechanisms independent of EGFR, such as the pathway bypass, which includes amplification of ERBB family receptors like HER2 (ERBB2) and activation of MET signaling. To overcome these resistances, novel strategies have emerged, which target multiple nodes within the oncogenic networks. Such methods include vertical pathway inhibition, multi-kinase inhibition, liquid-biopsy-guided therapy, and anti-EGFR rechallenge. Reactivation driven by secondary mutation can be prevented by targeting multiple nodes within the MAPK cascade simultaneously, which is referred to as the vertical pathway inhibition. Overall, this review underscores that overcoming therapeutic resistance requires a multidimensional approach that integrates molecular profiling, rational combination therapies, and adaptive treatment. Finally, these advances underscore the shift toward precision oncology, where therapy is tailored to tumor evolution, leading to improved response and patient outcome.

Verified 2026-10-10 · 3 references not checked yet

Overview

CoChat Summary

TL;DR

This review summarizes primary and acquired resistance mechanisms to cetuximab and panitumumab in metastatic colorectal cancer, emphasizing RAS/BRAF/PIK3CA alterations, bypass receptor signaling, and tumor microenvironment effects. It outlines emerging biomarker-guided combination strategies, including vertical pathway inhibition, HER2/MET blockade, and ctDNA/NGS monitoring.

Key findings

  • RAS mutations account for approximately 40% of metastatic colorectal cancers and are established negative predictors of anti-EGFR response; expanded RAS mutations beyond KRAS exon 2 also predict resistance. BRAF V600E occurs in about 10–15% of CRCs, PIK3CA mutations in 15–20%, PTEN loss in 20–40% of mCRC, and HER2 amplification in 2–5% of all mCRC but up to 10–15% in RAS wild-type tumors.
  • Acquired resistance develops within 12–18 months after initial response, driven by secondary KRAS mutations, EGFR ectodomain alterations such as S492R (cetuximab-resistant but panitumumab-sensitive), and clonal selection; bypass mechanisms include HER2/MET amplification, CAF-derived HGF/NRG1, EMT, hypoxia, and immunosuppressive microenvironment signaling.
  • Combination strategies show clinical activity: BEACON CRC (encorafenib plus cetuximab improved overall survival), BREAKWATER (encorafenib, cetuximab, and mFOLFOX6 improved PFS and OS in first-line BRAF-mutant mCRC), CodeBreaK 300 (sotorasib plus panitumumab improved PFS in KRAS G12C), HER2-directed trials (HERACLES, MyPathway, DESTINY-CRC01, MOUNTAINEER), MET/EGFR inhibition (PERSPECTIVE), and ctDNA-guided rechallenge (CRICKET, CAVE).
  • Liquid biopsy with ctDNA/NGS enables real-time detection of resistance mutations and negative hyperselection, but limitations include standardization, assay performance, cost, limited tumor shedding, and false negatives from low ctDNA shedding.

Methods

  • Narrative review with a literature search conducted from 15 April to 20 May 2026 using PubMed, Scopus, Google Scholar, ResearchGate, and other sources; search terms covered cetuximab/panitumumab, colorectal cancer/metastatic colorectal cancer, resistance mechanisms, and combination therapy.
  • PRISMA 2020 flow: 3326 records identified; after removing duplicates (n = 1244) and pre-2001/other records (n = 188), 1894 records were screened; 1810 were excluded, leaving 84 full-text records that met eligibility criteria.
  • Inclusion criteria prioritized English-language peer-reviewed original research, clinical trials, experimental studies, reviews, and high-quality conference abstracts published between 2001 and May 2026 on mCRC treated with cetuximab or panitumumab, resistance mechanisms, and combination strategies; no primary data were collected.

Limitations

  • The paper states that restricted institutional access to certain journals and databases may have limited retrieval of some full-text articles.
  • The paper states that liquid biopsy/ctDNA approaches are limited by standardization, assay performance, economic feasibility, limited tumor shedding, restricted access to the bloodstream, and false negatives due to low shedding.
  • Evident from the text: this is a narrative review without meta-analysis or quantitative synthesis, relying on published literature and potentially subject to selection or publication bias; the search was restricted to English-language records from 2001 to May 2026.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ph19071041

Cites

83 of 90 references verified0 citation errors · 4 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 PRISMA flow diagram of the included studies.
Figure 1 PRISMA flow diagram of the included studies.CC BY · PubMed Central
Figure 2 Schematic representation of EGFR signaling pathways and mechanisms of resistance to anti-EGFR monoclonal antibodies (cetuximab and panitumumab). Ligand-bound EGFR activates two main downstream cascades: the MAPK pathway (RAS-RAF-MEK-ERK) and the PI3K-AKT-mTOR axis (via PIP2/PIP3). Anti-EGFR monoclonal antibodies block receptor activation. Resistance arises through mutations in KRAS, NRAS, BRAF, PIK3CA, EGFR ectodomain, PTEN loss, and HER2 amplification, leading to uncontrolled proliferation, survival, and invasion. Green boxes: MAPK pathway, purple boxes: PI3K-AKT-mTOR axis, and red boxes: resistance mechanisms and mutations. Abbreviations: AKT—protein kinase B (PKB); BRAF-B—rapidly accelerated fibrosarcoma; EGFR—epidermal growth factor receptor; ERK—extracellular signal-regulated kinase; GDP—guanosine diphosphate; GTP—guanosine triphosphate; HER2—human epidermal growth factor receptor 2; HER3—human epidermal growth factor receptor 3; KRAS—Kirsten rat sarcoma virus; MAPK—mitogen-activated protein kinase; MEK—mitogen-activated protein kinase kinase; mTOR—mammalian target of rapamycin; NRAS—neuroblastoma rat sarcoma virus; PI3K—phosphoinositide 3-kinase; PIK3CA—phosphatidylinositol 4,5 bisphosphate 3 kinase catalytic subunit alpha; PIP—phosphatidylinositol 4,5 bisphosphate; PIP3—phosphatidylinositol (3,4,5) trisphosphate; PTEN—phosphatase and tensin homolog; RAF—rapidly accelerated fibrosarcoma; RAS—rat sarcoma virus.
Figure 2 Schematic representation of EGFR signaling pathways and mechanisms of resistance to anti-EGFR monoclonal antibodies (cetuximab and panitumumab). Ligand-bound EGFR activates two main downstream cascades: the MAPK pathway (RAS-RAF-MEK-ERK) and the PI3K-AKT-mTOR axis (via PIP2/PIP3). Anti-EGFR monoclonal antibodies block receptor activation. Resistance arises through mutations in KRAS, NRAS, BRAF, PIK3CA, EGFR ectodomain, PTEN loss, and HER2 amplification, leading to uncontrolled proliferation, survival, and invasion. Green boxes: MAPK pathway, purple boxes: PI3K-AKT-mTOR axis, and red boxes: resistance mechanisms and mutations. Abbreviations: AKT—protein kinase B (PKB); BRAF-B—rapidly accelerated fibrosarcoma; EGFR—epidermal growth factor receptor; ERK—extracellular signal-regulated kinase; GDP—guanosine diphosphate; GTP—guanosine triphosphate; HER2—human epidermal growth factor receptor 2; HER3—human epidermal growth factor receptor 3; KRAS—Kirsten rat sarcoma virus; MAPK—mitogen-activated protein kinase; MEK—mitogen-activated protein kinase kinase; mTOR—mammalian target of rapamycin; NRAS—neuroblastoma rat sarcoma virus; PI3K—phosphoinositide 3-kinase; PIK3CA—phosphatidylinositol 4,5 bisphosphate 3 kinase catalytic subunit alpha; PIP—phosphatidylinositol 4,5 bisphosphate; PIP3—phosphatidylinositol (3,4,5) trisphosphate; PTEN—phosphatase and tensin homolog; RAF—rapidly accelerated fibrosarcoma; RAS—rat sarcoma virus.CC BY · PubMed Central
Figure 3 Schematic overview of the major mechanisms of resistance to anti-EGFR monoclonal antibodies (cetuximab and panitumumab) in metastatic colorectal cancer (mCRC). Therapeutic resistance arises through multiple genetic and microenvironmental alterations that bypass or reactivate the downstream signaling pathways. (A) MAPK pathway activation: RAS mutations (approximately 40% of mCRC) and BRAF mutations (BRAF V600E, approximately 10–15% of mCRC) constitutively activate the MAPK cascade (RAF-MEK-ERK) downstream signals, rendering anti-EGFR antibodies ineffective. (B) PI3K-AKT-mTOR pathway activation: PIK3CA mutations (approximately 15–20% of mCRC) and PTEN loss (approximately 20–40% of mCRC) lead to sustained PI3K-AKT-mTOR signaling, promoting cell survival and proliferation independently of upstream EGFR blockade. (C) HER2 bypass signaling: HER2 amplification (2–5% of mCRC) and HER2/HER3 heterodimerization activate both MAPK and PI3K pathways in RAS wild-type tumors (10–20% of resistance cases), independent of EGFR inhibition. (D) MET amplification and HER3 transactivation: MET amplification (22–40% of cases post-anti-EGFR therapy) transactivates HER3, reactivating downstream MAPK and PI3K signaling. (E) IGF-1R bypass signaling: activation of insulin-like growth factor 1 receptor (IGF-1R) by its ligands (IGF-1 and IGF-2) provides an alternative route to MAPK and PI3K activation. (F) EGFR ectodomain mutations: mutations in the extracellular domain of EGFR prevent binding of cetuximab and panitumumab while preserving receptor activation. (G) Tumor microenvironment: cancer-associated fibroblasts secrete ligands, promoting resistance through paracrine signaling.
Figure 3 Schematic overview of the major mechanisms of resistance to anti-EGFR monoclonal antibodies (cetuximab and panitumumab) in metastatic colorectal cancer (mCRC). Therapeutic resistance arises through multiple genetic and microenvironmental alterations that bypass or reactivate the downstream signaling pathways. (A) MAPK pathway activation: RAS mutations (approximately 40% of mCRC) and BRAF mutations (BRAF V600E, approximately 10–15% of mCRC) constitutively activate the MAPK cascade (RAF-MEK-ERK) downstream signals, rendering anti-EGFR antibodies ineffective. (B) PI3K-AKT-mTOR pathway activation: PIK3CA mutations (approximately 15–20% of mCRC) and PTEN loss (approximately 20–40% of mCRC) lead to sustained PI3K-AKT-mTOR signaling, promoting cell survival and proliferation independently of upstream EGFR blockade. (C) HER2 bypass signaling: HER2 amplification (2–5% of mCRC) and HER2/HER3 heterodimerization activate both MAPK and PI3K pathways in RAS wild-type tumors (10–20% of resistance cases), independent of EGFR inhibition. (D) MET amplification and HER3 transactivation: MET amplification (22–40% of cases post-anti-EGFR therapy) transactivates HER3, reactivating downstream MAPK and PI3K signaling. (E) IGF-1R bypass signaling: activation of insulin-like growth factor 1 receptor (IGF-1R) by its ligands (IGF-1 and IGF-2) provides an alternative route to MAPK and PI3K activation. (F) EGFR ectodomain mutations: mutations in the extracellular domain of EGFR prevent binding of cetuximab and panitumumab while preserving receptor activation. (G) Tumor microenvironment: cancer-associated fibroblasts secrete ligands, promoting resistance through paracrine signaling.CC BY · PubMed Central
Figure 4 Treatment strategy for patients with metastatic colorectal cancer (mCRC) based on liquid biopsy. This schematic diagram illustrates the liquid-biopsy-driven rechallenge strategy for metastatic colorectal cancers (mCRCs). Following first-line anti-EGFR therapy, tumor progression leads to the shedding of tumor components, such as circulating tumor DNA (ctDNA), into the bloodstream. A blood sample is collected, from which various liquid biopsy analytes (such as CTCs, cfRNAs, ctDNAs, EVs, miRNAs, and TEPs) are extracted. Molecular profiling via next-generation sequencing (NGS) identifies alterations in key genes (e.g., RAS, BRAF, ERK, MEK, EGFR-ECD, HER2, MET, and others). Upon treatment withdrawal, ctDNA clearance is observed, enabling a rechallenge strategy with anti-EGFR therapy when the tumor returns to a wild-type (WT) status, as guided by longitudinal ctDNA monitoring. Abbreviations: anti-EGFR—anti-epidermal growth factor receptor; CTCs—circulating tumor cells; cfRNAs—cell-free RNAs; EVs—extracellular vesicles; miRNAs—microRNAs; TEPs—tumor educated platelets; NGS—next-generation sequencing; WT—wild-type; RAS—rat sarcoma viral oncogene; BRAF—v-RAF murine sarcoma viral oncogene homolog B1; ERK—extracellular signal-regulated kinase; MEK—mitogen-activated protein kinase kinase; EGFR-ECD—epidermal growth factor receptor extracellular domain; HER2—human epidermal growth factor receptor 2; MET—mesenchymal-to-epithelial transition factor.
Figure 4 Treatment strategy for patients with metastatic colorectal cancer (mCRC) based on liquid biopsy. This schematic diagram illustrates the liquid-biopsy-driven rechallenge strategy for metastatic colorectal cancers (mCRCs). Following first-line anti-EGFR therapy, tumor progression leads to the shedding of tumor components, such as circulating tumor DNA (ctDNA), into the bloodstream. A blood sample is collected, from which various liquid biopsy analytes (such as CTCs, cfRNAs, ctDNAs, EVs, miRNAs, and TEPs) are extracted. Molecular profiling via next-generation sequencing (NGS) identifies alterations in key genes (e.g., RAS, BRAF, ERK, MEK, EGFR-ECD, HER2, MET, and others). Upon treatment withdrawal, ctDNA clearance is observed, enabling a rechallenge strategy with anti-EGFR therapy when the tumor returns to a wild-type (WT) status, as guided by longitudinal ctDNA monitoring. Abbreviations: anti-EGFR—anti-epidermal growth factor receptor; CTCs—circulating tumor cells; cfRNAs—cell-free RNAs; EVs—extracellular vesicles; miRNAs—microRNAs; TEPs—tumor educated platelets; NGS—next-generation sequencing; WT—wild-type; RAS—rat sarcoma viral oncogene; BRAF—v-RAF murine sarcoma viral oncogene homolog B1; ERK—extracellular signal-regulated kinase; MEK—mitogen-activated protein kinase kinase; EGFR-ECD—epidermal growth factor receptor extracellular domain; HER2—human epidermal growth factor receptor 2; MET—mesenchymal-to-epithelial transition factor.CC BY · PubMed Central

Verification

Claims the paper makes

47 Valid · 6 Not valid · 4 Not checked · 49 Own results and interpretations

52 more claims · 18 with their cited sources checked

Create a free account to see all 106 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 44
  • Probably not a substantial claim. 11

Create a free account to see these claims.

Citations

Cites

Show all 84 references

Cited by

See all 1

Metadata

Authors
Henrykowska, G., Bartusik-Aebisher, D., Dynarowicz, K., Ramesh, T. S., Smolak, B., & Aebisher, D.
Affiliations
  • Medical University of Lodz (PL)
  • Department of Biochemistry and General Chemistry, Faculty of Medicine, University of Rzeszów, 35-310 Rzeszów, Poland
  • University of Rzeszów (PL)
Corresponding author
  • Henrykowska, Gabriela
  • Aebisher, David
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2026-07-03
Volume
19
Issue
7
Pages
1041
ISSN
1424-8247 (ISSN-L)
OpenAlex
W7167210935
Cited by
1
References
84
Citations by year
2026: 1
FWCI
0.84
Type
journal article
Language
en
Open access
Locations
  • Pharmaceuticals (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
cetuximab, panitumumab, anti-EGFR therapy resistance, colorectal cancer, KRAS mutation, BRAF mutation, RAS/MAPK pathway, PI3K/Akt signaling, clonal evolution, HER2 amplification, C-MET signaling, multikinase inhibitor, liquid biopsy, combination therapy, precision oncology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies. https://app.cochat.ai/papers/10.3390/ph19071041
The paper
Henrykowska, G., Bartusik-Aebisher, D., Dynarowicz, K., Ramesh, T. S., Smolak, B., & Aebisher, D. (2026). Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies. Pharmaceuticals. https://doi.org/10.3390/ph19071041

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.